PTK2B(PYK2)
Sign in to save this workspaceUniProt Q14289 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 99.1% | 0.9% | 82.96 | 0.513 |
| 2 | Lorlatinib | 97.6% | 2.4% | 97.24 | 0.694 |
| 3 | Ponatinib | 96.4% | 3.6% | 78.23 | 0.534 |
| 4 | Crizotinib | 95.1% | 4.9% | 91.39 | 0.581 |
| 5 | Repotrectinib | 92.7% | 7.3% | 84.21 | 0.608 |
| 6 | Ceritinib | 89.7% | 10.3% | 95.44 | 0.618 |
| 7 | Defactinib | 88.0% | 12.0% | 92.68 | 0.450 |
| 8 | Alectinib | 85.1% | 14.9% | 95.49 | 0.651 |
| 9 | Fostamatinib | 84.9% | 15.1% | 96.74 | 0.613 |
| 10 | Gilteritinib | 81.8% | 18.2% | 88.97 | 0.506 |
| 11 | Sunitinib | 75.7% | 24.3% | 91.73 | 0.524 |
| 12 | Bosutinib | 69.1% | 30.9% | 87.22 | 0.555 |
| 13 | Entrectinib | 68.6% | 31.4% | 93.69 | 0.671 |
| 14 | Pacritinib | 64.0% | 36.0% | 88.64 | 0.452 |
| 15 | Midostaurin | 60.3% | 39.7% | 78.64 | 0.500 |
| 16 | Pralsetinib | 59.2% | 40.8% | 93.43 | 0.643 |
| 17 | Abemaciclib | 57.3% | 42.7% | 91.48 | 0.563 |
| 18 | Cabozantinib | 55.4% | 44.6% | 92.73 | 0.751 |
| 19 | Fedratinib | 50.0% | 50.0% | 96.21 | 0.576 |
| 20 | Osimertinib | 49.0% | 51.0% | 97.24 | 0.733 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.03
- Epithelial log2(TPM+1): 3.02
- Fold change: -1.00
- Status: No significant change
Selectivity landscape vs inhibition on PTK2B
Each point is one of the 92 approved drugs; color = inhibition % on PTK2B.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…